News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,302 Results
Type
Article (38969)
Company Profile (276)
Press Release (644057)
Section
Business (203823)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80770)
Employer Resources (168)
FDA (16085)
Job Trends (14797)
News (344465)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16004)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11465)
Biotechnology (196)
Breast cancer (107)
Cancer (901)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (198)
Clinical research (63922)
Collaboration (326)
Compensation (168)
COVID-19 (2522)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6096)
Earnings (84159)
Employer resources (146)
Events (108852)
Executive appointments (247)
FDA (16529)
Funding (289)
Gene therapy (149)
GLP-1 (558)
Government (4318)
Healthcare (18652)
Infectious disease (2597)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16271)
Job creations (3622)
Job search strategy (1415)
Layoffs (408)
Legal (7848)
Lung cancer (154)
Manufacturing (151)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19108)
Metabolic disorders (364)
Neuroscience (1456)
NextGen Class of 2024 (6496)
Non-profit (4462)
Northern California (1206)
Obesity (216)
Opinion (176)
Patents (94)
People (56126)
Phase I (19824)
Phase II (28144)
Phase III (21015)
Pipeline (212)
Postmarket research (2553)
Preclinical (8429)
Radiopharmaceuticals (234)
Rare diseases (180)
Real estate (5888)
Regulatory (21441)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1082)
Startups (3560)
United States (11658)
Vaccines (537)
Weight loss (160)
Date
Today (236)
Last 7 days (851)
Last 30 days (2912)
Last 365 days (35686)
2024 (30409)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (187)
Asia (37012)
Australia (6037)
California (2727)
Canada (1178)
China (209)
Colorado (117)
Connecticut (122)
Europe (79239)
Florida (394)
Georgia (100)
Illinois (306)
Indiana (177)
Kansas (95)
Maryland (515)
Massachusetts (2227)
Michigan (143)
Minnesota (250)
New Jersey (827)
New York (840)
North Carolina (665)
Northern California (1206)
Ohio (127)
Pennsylvania (747)
South America (1091)
Southern California (1082)
Texas (383)
Utah (80)
Washington State (322)
683,302 Results for "orphomed inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced positive results from the recent Phase 2 study of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).
January 4, 2022
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Drug Development
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully passed a second interim futility analysis triggered by enrollment of 260 patients in its Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).
April 14, 2021
·
4 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
Press Releases
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
November 4, 2024
·
1 min read
Press Releases
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
November 5, 2024
·
7 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 24, 2024
·
4 min read
1 of 68,331
Next